Authors
|
Year
|
Title
|
Journal and link to the article
|
| Mucci et al. |
2019 |
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. |
European Neuropsychopharmacology |
| Kahn et al. |
2018
|
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. |
Lancet Psychiatry |
| Volavka et al. |
2016
|
Hostility in schizophrenia: an integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. |
European Psychiatry |
| Landolt et al. |
2016 |
Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). |
Schizophrenia Bulletin |
| Leucht et al. |
2015 |
The optimization of treatment and management of schizophrenia in Europe. (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. |
Schizophrenia Bulletin |
| Dazzan et al. |
2015 |
Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research |
Schizophrenia Bulletin |
| Arango et al. |
2015
|
Going beyond "trial-and-error" in psychiatric treatments: OPTiMiSE-ing the treatment of first episode of schizophrenia |
Schizophrenia Bulletin |
| Czobor et al. |
2015 |
Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. |
European Neuropsychopharmacology |
| Pijnenborg et al. |
2015 |
Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST) |
European Neuropsychopharmacology |
| Rybakowski et al. |
2014 |
Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. |
European Neuropsychopharmacology |
| Reis Marques et al. |
2014 |
How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. |
European Neuropsychopharmacology |
| Wobrock et al. |
2013 |
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. |
Schizophrenia Research |
| Riecher-Rossler et al. |
2013 |
Hyperprolactinemia in antipsychotic naïve patients with first episode psychosis – results from EUFEST. |
Psychological Medicine |
| Czobor et al. |
2013 |
Insight and hostility as predictors and correlates of non-adherence in the European First Episode Schizophrenia Trial (EUFEST). |
Journal of Clinical Psychopharmacology |
| Fleischhacker et al. |
2013 |
Metabolic Risk Factors in First Episode Schizophrenia: Prevalence and Course Analyzed from the European First Episode Schizophrenia Trial (EUFEST). |
International Journal of Neuropsychopharmacology |
| Galderisi et al. |
2013 |
Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. |
European Neuropsychopharmacology |
| Rybakowski et al. |
2012
|
Treatment of depression in first episode of schizophrenia: Results from EUFEST. |
European Neuropsychopharmacology |
| Dollfus et al. |
2012
|
Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study. |
Laterality |
| Fleischhacker et al. |
2012
|
Interpreting treatment trials in schizophrenia patients: Lessons learned from EUFEST. |
Schizophrenia Research |
| Landolt et al. |
2012
|
The interrelation of needs and quality of life in first-episode schizophrenia. |
European Archives of Psychiatry and Clinical Neuroscience |
| Landolt et al. |
2012
|
Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. |
Psychological Medicine |
| Volavka et al. |
2011 |
Efficacy of antipsychotic drugs against hostility in the European First Episode Schizophrenia Trial (EUFEST). |
Journal of Clinical Psychiatry |
| Malik et al. |
2011 |
Sexual dysfunction in first-episode schizophrenia patients: results from European first episode schizophrenia trial. |
Journal of Clinical Psychopharmacology |
| Derks et al. |
2010
|
Should patients be switched to a different antipsychotic drug after 2, 4 or 6 week of non response? |
Journal of Clinical Psychopharmacology |
| Boter et al. |
2010
|
Generalizability of the results of efficacy trials in first episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST) |
Journal of Clinical Psychiatry |
| Gaebel et al. |
2010
|
Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). |
European Neuropsychopharmacology |
| Boter et al. |
2009 |
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder in response and remission: an open randomized clinical trial (EUFEST). |
Schizophrenia Research |
| Galderisi et al. |
2009
|
Correlates of cognitive impairment in first episode schizophrenia. The EUFEST study. |
Schizophrenia Research |
| Davidson et al. |
2009 |
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open label clinical trial (EUFEST). |
American Journal of Psychiatry |
| Kahn et al. |
2008 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. |
The Lancet |
| Fleischhacker et al. |
2005
|
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. |
Schizophrenia Research |
